Yeast-based vaccines: New perspective in vaccine development and application

Kumar, Romesh; Kumar, Piyush

doi:10.1093/femsyr/foz007

Cited by 109 publications

(94 citation statements)

References 263 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the reasons for interest in recombinant S.cerevisiae as a vaccine vehicle is its lacking of toxicity [8]. Besides being inherently nonpathogenic, this particular species of yeast can be heat-killed before administration and has been shown to be safe in humans in several clinical trials, with maximum tolerated dose not reached [19,20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

et al. 2020

View full text Add to dashboard Cite

Background: Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently. Results: An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/ Anhui/1/2013 (AH-H7N9) virus challenge. Conclusions: Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Saccharomyces cerevisiae (S.cerevisiae), a nonpathogenic yeast, is an ideal organism to express viral or tumor antigens, and is the most common host for cell surface display [7,8]. Recently, influenza H5N1 HA has been expressed on the surface of S.cerevisiae by C-terminal display expression plasmid pYD1 [9].…”

Section: Introductionmentioning

confidence: 99%

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Most importantly, recombinant S. cerevisiae has been shown to induce a strong host immune response to non-self-antigens [21,22,23]. In addition to the convenience of production, for purposes of vaccination, yeast has been shown to have natural adjuvant activity making the expressed proteins more immunogenic when administered along with yeast cell wall components [8]. Development of genetic systems to display foreign proteins on the surface of yeast via fusion to glycosylphosphatidylinositol-anchored (GPI) proteins has further simplified the purification of recombinant proteins by not requiring harsh treatments for cellular lysis or protein purification [24].…”

Section: Discussionmentioning

confidence: 99%

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

Han

Xie

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently. Results An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge. Conclusions Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic. Keywords: S.cerevisiae EBY100/pYD5-HA, Yeast display technology, Influenza A pandemic.

show abstract

“…S. cerevisiae SIC, generated using the pSynInsCPOT plasmid for increased insulin production when compared with the conventional strain, is a representative example [26,27]. Beyond S. cerevisiae, P. pastoris has been used to produce the human p53 tumor suppressor protein [28], and Schizosaccharomyces pombe has been widely used to produce hepatitis vaccines [24].…”

Section: Wine Beer and Breadmentioning

confidence: 99%

Anti-Contamination Strategies for Yeast Fermentations

Seo

Park

Jung³

et al. 2020

Microorganisms

View full text Add to dashboard Cite

Yeasts are very useful microorganisms that are used in many industrial fermentation processes such as food and alcohol production. Microbial contamination of such processes is inevitable, since most of the fermentation substrates are not sterile. Contamination can cause a reduction of the final product concentration and render industrial yeast strains unable to be reused. Alternative approaches to controlling contamination, including the use of antibiotics, have been developed and proposed as solutions. However, more efficient and industry-friendly approaches are needed for use in industrial applications. This review covers: (i) general information about industrial uses of yeast fermentation, (ii) microbial contamination and its effects on yeast fermentation, and (iii) currently used and suggested approaches/strategies for controlling microbial contamination at the industrial and/or laboratory scale.

show abstract

Yeast-based vaccines: New perspective in vaccine development and application

Cited by 109 publications

References 263 publications

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

Anti-Contamination Strategies for Yeast Fermentations

Contact Info

Product

Resources

About